What changed from existing technology?
This study tested a new vaccine made with a modified virus that carries two parts of the Crimean-Congo hemorrhagic fever virus. It showed better immune responses in mice than vaccines with just one part.
This study is the first to evaluate a dual-antigen AdV5 vaccine for CCHFV, showing improved immune responses compared to single-antigen vaccines.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 0
- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
- 장기·실사용 검증 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This vaccine platform could be explored for further development as a potential candidate for CCHFV immunization strategies.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.